Argenx Se (ARGX) AI Stock Analysis

• Market Cap: $55.73B
• Dividend Yield: N/A
• Average Volume (3M): 357.82K
• Price to Earnings (P/E): 41.9
• Beta (1Y): 0.22
• Revenue Growth: 89.58%
• EPS Growth: N/A
• Country: US
• Employees: 1,599
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 5.18
• Shares Outstanding: 61,568,928
• 10 Day Avg. Volume: 369,574
• 30 Day Avg. Volume: 357,816
• PEG Ratio: -0.12
• Price to Book (P/B): 6.70
• Price to Sales (P/S): 16.81
• P/FCF Ratio: -243.71
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $951.44
• Price Target Upside: 4.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 21
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 79 Outperform
• Price Target: $1,040.00 ▲(14.54% Upside)

Argenx Se's strong financial performance and bullish technical indicators are the primary drivers of its high stock score. The company's robust revenue growth and strategic advancements in its pipeline are significant positives. However, the high valuation and operational challenges in cash flow generation slightly temper the overall score.

Positive Factors

Revenue Growth

The substantial year-over-year revenue growth indicates strong market demand and successful product adoption, enhancing long-term financial stability.

Regulatory Approval

Regulatory approval in new indications expands market reach and potential revenue streams, strengthening Argenx's competitive position in the biotech industry.

Pipeline Progress

Advancing multiple candidates to late-stage trials demonstrates robust R&D capabilities and potential for future product launches, supporting long-term growth.

Negative Factors

Operational Challenges

Operational challenges in clinical trials can delay product development and impact the company's ability to bring new therapies to market.

Increased Operating Expenses

Rising operating expenses may pressure profit margins and require efficient cost management to sustain long-term profitability.

Cash Flow Inefficiencies

Inefficiencies in converting income into cash flow can strain liquidity and limit the company's ability to fund operations and growth initiatives.

Argenx Se Business Overview & Revenue Model

Company Description

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

How the Company Makes Money

Argenx generates revenue primarily through the development and commercialization of its therapeutic candidates. Key revenue streams include product sales from approved therapies, milestone payments from partnerships, and royalties from licensed products. The company has established strategic collaborations with major pharmaceutical firms, which provide upfront payments and contingent milestone payments tied to the development and commercialization of its products. Additionally, Argenx may receive royalties based on the future sales of partnered products, contributing to its overall earnings. The successful advancement of its clinical pipeline, especially the commercialization of efgartigimod, plays a pivotal role in its revenue generation strategy.

Argenx Se Financial Statement Overview

Summary

Argenx Se has demonstrated robust revenue growth and improved profitability, backed by a strong balance sheet with minimal leverage. However, the company faces challenges in operational efficiency and cash flow generation, which are critical areas for improvement to sustain long-term growth.

Income Statement

Argenx Se has shown a significant increase in total revenue from 2023 to 2024, with a revenue growth rate of 77.32%. The company has also improved its profitability, turning a net income of $804 million in 2024 from a net loss of $295 million in 2023. However, the EBIT margin remains negative, indicating ongoing operational challenges.

Balance Sheet

The company's balance sheet is strong, with a high equity ratio of 88.64% and a low debt-to-equity ratio of 0.007. This indicates financial stability and low leverage, reducing financial risk. The return on equity has improved significantly due to positive net income, which enhances shareholder value.

Cash Flow

Argenx Se has managed to improve its free cash flow position slightly, but it remains negative. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in converting income into cash flow. However, the company has strong financing activities that continue to support its cash position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.29B	2.19B	1.23B	410.75M	497.28M	41.24M
Gross Profit	1.52B	1.96B	1.11B	381.31M	497.28M	41.24M
EBITDA	640.57M	105.17M	-192.28M	-622.78M	-392.78M	-601.03M
Net Income	1.11B	833.04M	-295.05M	-709.59M	-407.63M	-608.46M
Balance Sheet
Total Assets	7.18B	6.20B	4.54B	3.13B	2.85B	2.28B
Cash, Cash Equivalents and Short-Term Investments	3.93B	3.38B	3.18B	2.19B	2.34B	2.00B
Total Debt	43.15M	39.05M	20.00M	12.43M	11.46M	12.50M
Total Liabilities	1.08B	704.24M	444.95M	320.56M	316.05M	605.36M
Stockholders Equity	6.10B	5.50B	4.10B	2.81B	2.53B	1.67B
Cash Flow
Free Cash Flow	473.52M	-151.05M	-464.14M	-966.63M	-728.25M	-403.60M
Operating Cash Flow	479.76M	-82.75M	-420.33M	-862.81M	-606.81M	-398.46M
Investing Cash Flow	-214.14M	-717.59M	308.21M	-461.18M	-347.07M	344.69M
Financing Cash Flow	313.76M	279.76M	1.34B	843.76M	1.12B	833.00M

Argenx Se Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 907.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARGX, the sentiment is Positive. The current price of 907.98 is above the 20-day moving average (MA) of 844.99, above the 50-day MA of 799.34, and above the 200-day MA of 655.28, indicating a bullish trend. The MACD of 27.47 indicates Negative momentum. The RSI at 80.37 is Negative, neither overbought nor oversold. The STOCH value of 86.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ARGX.

Argenx Se Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
INCY	81 Outperform	$21.25B	17.68	30.39%	―	18.09%	3563.21%
ARGX	79 Outperform	$55.73B	41.89	24.75%	―	89.58%	―
REGN	79 Outperform	$72.89B	16.60	15.19%	0.40%	2.89%	0.50%
GMAB	76 Outperform	$18.85B	12.74	28.20%	―	24.98%	127.06%
ALNY	57 Neutral	$59.81B	1,888.39	32.73%	―	53.24%	―
BNTX	53 Neutral	$26.86B	―	-2.94%	―	7.04%	-25.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Argenx Se Corporate Events

Argenx SE Reports Strong Q3 2025 Financial Results and Strategic Advances

On October 30, 2025, Argenx SE reported its third quarter financial results, showcasing a significant increase in global product net sales to $1.13 billion, driven by strong demand for VYVGART. The company is on track to submit a supplemental Biologics License Application for VYVGART in seronegative gMG subtypes by year-end and anticipates multiple registrational study readouts in 2026. Argenx is also expanding its manufacturing capabilities in partnership with FUJIFILM, enhancing its supply chain to support future growth. These developments underscore Argenx’s strategic focus on innovation and its Vision 2030 goals, aiming to treat 50,000 patients globally and secure 10 labeled indications across its medicines.

Argenx SE Highlights VYVGART’s Efficacy in Treating Myasthenia Gravis

On October 29, 2025, Argenx SE presented new data at the AANEM and MGFA meetings highlighting the efficacy and safety of VYVGART for gMG patients. The data demonstrated significant improvements in patient outcomes, including reduced steroid use and sustained minimal symptom expression, positioning VYVGART as a potentially transformative treatment for gMG across various patient subtypes. These findings underscore VYVGART’s potential to redefine treatment standards and improve quality of life for patients, with plans to seek label expansion to include additional patient subtypes.

Argenx SE Showcases Immunology Innovations at 2025 AANEM Meeting

On October 15, 2025, Argenx SE announced its participation in the 2025 AANEM Annual Meeting and MGFA Scientific Session, where it will present pivotal data on VYVGART and empasiprubart. The company highlighted the potential of VYVGART in treating myasthenia gravis and other neuromuscular diseases, showcasing results from various studies that demonstrate its efficacy and safety. This presentation underscores Argenx’s commitment to advancing innovative therapies and improving patient outcomes in the field of autoimmune and neuromuscular diseases.

Argenx SE Calls Extraordinary Shareholder Meeting for November 2025

On October 3, 2025, Argenx SE announced that it will hold an Extraordinary General Meeting of Shareholders on November 18, 2025, in Amsterdam. The meeting will address the adoption of a revised remuneration policy, and shareholders are encouraged to participate via electronic proxy voting. This meeting is significant for stakeholders as it may impact the company’s governance and strategic direction.

argenx Reports Positive Results from ADAPT SERON Study for VYVGART

On August 25, 2025, argenx announced positive topline results from its ADAPT SERON study of VYVGART in patients with AChR-Ab seronegative gMG. The study met its primary endpoint, showing significant improvement in patients’ MG-ADL scores, and demonstrated VYVGART’s potential as a targeted treatment across all AChR-Ab seronegative subtypes. The company plans to submit a supplemental Biologics License Application to the FDA by the end of 2025, aiming to expand VYVGART’s label to include these patient subtypes. This advancement highlights argenx’s commitment to addressing the unmet needs of the MG community and could significantly impact its industry positioning.